Lupin Ltd.’s wholly owned subsidiary VISUfarma has entered an exclusive licensing agreement with Tenpoint Therapeutics to commercialize YUVEZZI, a once-daily dual-agent eye drop for adults with presbyopia, across the European Union, the United Kingdom, Switzerland, Norway and Iceland.
The agreement gives VISUfarma exclusive responsibility for regulatory activities, commercialization, marketing, promotion, distribution and sales of YUVEZZI in the licensed territories. The product contains carbachol and brimonidine tartrate ophthalmic solution at 2.75% and 0.1%, respectively.
As part of the arrangement, VISUfarma will make a strategic investment in Visus Therapeutics, Tenpoint’s U.S.-based wholly owned subsidiary. Tenpoint and Visus may also receive regulatory and commercial milestone payments, along with tiered royalties based on net sales. The companies did not disclose the investment amount, potential milestone values or royalty rates.
YUVEZZI is described as the first and only approved once-daily, dual-agent eye drop for presbyopia. Presbyopia is an age-related condition that affects near vision in adults.
Lupin Chief Executive Vinita Gupta said the partnership supports the company’s Specialty Care strategy and builds on its acquisition of VISUfarma. She said the agreement strengthens Lupin’s vision-care franchise and expands its presence in key European markets.
“The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories,” Gupta said.
Tenpoint Chief Executive Henric Bjarke said the arrangement advances the company’s objective of making YUVEZZI available to patients with presbyopia and eye-care professionals globally. He said Lupin’s commercial operations across major European markets and VISUfarma’s established presence in ophthalmology made the companies suitable partners.
Tenpoint is advancing commercialization of YUVEZZI in the United States following recent FDA approval. The company has also submitted a marketing authorization application in the United Kingdom through the Medicines and Healthcare products Regulatory Agency’s International Recognition Procedure.
Tenpoint said it plans to pursue regulatory applications in other key markets. The VISUfarma agreement extends its regional partnership strategy as it seeks broader international availability for YUVEZZI.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!